Heart failure and COVID-19
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR (2020 Feb) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 17:105924
COVID-19 Map [Internet] (2020) Johns Hopkins Coronavirus Resource Center. [cited 27 April 2020]. Available from: https://coronavirus.jhu.edu/map.html. Accessed 27 Apr 2020
WHO Director-General’s opening remarks at the media briefing on COVID-19 - 3 March 2020 [Internet]. Who.int. (2020). Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-3-march-2020. Accessed 27 Apr 2020
Novel CP (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41(2):145
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5(7):802–810. https://doi.org/10.1001/jamacardio.2020.0950
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN (2020) Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 382(25):e102. https://doi.org/10.1056/NEJMoa2007621
Ng TM, Toews ML (2016) Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. World J Cardiol 8(10):584–589
Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, Nichol K, Wright JD, Solomon SD, Vardeny O (2019) Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study. JAMA Cardiol 4(4):363–369
Tufan A, GÜLER AA, Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50(SI-1):620–632
Kumar A, Parrillo JE, Kumar A (2002) Clinical review: myocardial depression in sepsis and septic shock. Crit Care 6(6):500
Dellinger RP (2003) Inflammation and coagulation: implications for the septic patient. Clin Infect Dis 36(10):1259–1265
Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, Kaptein FH, van Paassen J, Stals MA, Huisman MV, Endeman H (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 191:148–150. https://doi.org/10.1016/j.thromres.2020.04.041
Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46(6):1089–1098. https://doi.org/10.1007/s00134-020-06062-x
Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S (2020) Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 76(1):122–124. https://doi.org/10.1016/j.jacc.2020.05.001
Atallah B, Mallah SI, AlMahmeed W (2020) Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother 6(4):260–261. https://doi.org/10.1093/ehjcvp/pvaa036
DeFilippis EM, Reza N, Donald E, Givertz MM, Lindenfeld J, Jessup M (2020) Considerations for heart failure care during the coronavirus disease 2019 (COVID-19) pandemic. JACC Heart Fail S2213-1779(20)30273–0. https://doi.org/10.1016/j.jchf.2020.05.006
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8(5):475–481. https://doi.org/10.1016/S2213-2600(20)30079-5
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M (2020) Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 323(16):1612–1614
Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46(5):846–848. https://doi.org/10.1007/s00134-020-05991-x
Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, Spath N, Yucel-Finn A, Yuecel R, Oldroyd K, Dospinescu C (2019) Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. Circulation 139(13):1581–1592
Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, You LN, Lei P, Tan XW, Qin S, Cai GQ (2020) Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res 21(1):1–7
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513
Fang Z, Yi F, Wu K, Lai K, Sun X, Zhong N, Liu Z (2020) Clinical characteristics of 2019 coronavirus pneumonia (COVID-19): an updated systematic review. medRxiv
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323(16):1574–1581
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 369:m1985. https://doi.org/10.1136/bmj.m1985
Buckner FS, McCulloch DJ, Atluri V, Blain M, McGuffin SA, Nalla AK, Huang ML, Greninger AL, Jerome KR, Cohen SA, Neme S (2020) Clinical features and outcomes of 105 hospitalized patients with COVID-19 in Seattle, Washington. Clin Infect Dis ciaa632. https://doi.org/10.1093/cid/ciaa632
Almazeedi S, Al Youha S, Jamal MH, Al-Haddad M, Al-Muhaini A, Al-Ghimlas F, Al-Sabah S (2020) Clinical characteristics, risk factors and outcomes among the first consecutive 1,096 patients diagnosed with COVID-19: the Kuwait experience. medRxiv
Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh A, Yeganeh B, Mohseni S, Mehraein R, Sepidarkish M, Bijani A, Rostami A (2020) Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Rom J Intern Med;1(ahead-of-print) https://doi.org/10.2478/rjim-2020-0013
Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, Rabbani L, Brodie D, Jain SS, Kirtane A, Masoumi A (2020) The variety of cardiovascular presentations of COVID-19. Circulation 141(23):1930–1936. https://doi.org/10.1161/CIRCULATIONAHA.120.047164
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D (2020) Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol 75(18):2352–2371
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD (2018) Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 72(18):2231–2264
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Tikellis C, Thomas MC (2012) Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012:1–8
Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8(4):e21. https://doi.org/10.1016/S2213-2600(20)30116-8
Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383(1):45–51
Hamming I, Van Goor H, Turner AJ, Rushworth CA, Michaud AA, Corvol P, Navis G (2008) Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol 93(5):631–638
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 111(20):2605–2610
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047):112–116
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med 11(8):875–879
Li J, Wang X, Chen J, Zhang H, Deng A (2020) Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 5(7):1–6. https://doi.org/10.1001/jamacardio.2020.1624
ClinicalTrials.gov. Randomized controlled trial of losartan for patients with COVID-19 not requiring hospitalization. Identifier: NCT04311177. March 17, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04311177. Accessed 27 Apr 2020
ClinicalTrials.gov. Randomized controlled trial of losartan for patients with COVID-19 requiring hospitalization. Identifier: NCT04312009. March 17, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04312009. Accessed 27 Apr 2020
HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19 - American College of Cardiology [Internet]. American College of Cardiology. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 27 Apr 2020
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271
Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56(1):105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
[Internet]. Crediblemeds.org. [cited 1 May 2020]. Available from: https://www.crediblemeds.org/pdftemp/pdf/CombinedList.pdf. Accessed 1 May 2020
Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, Noto M, Oe T, Kaneko A (2015) Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther 53(10):866–874
Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E, INMI Ebola Team. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis 11(12):e0006034. https://doi.org/10.1371/journal.pntd.0006034
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ (2013) Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Cir Cardiovasc Qual Outcomes 6(4):479–487
Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL (2006) The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci 29(1):70–81
Somer M, Kallio J, Pesonen U, Pyykkö K, Huupponen R, Scheinin M (2000) Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 49(6):549–554
Gorodeski EZ, Goyal P, Cox ZL, Thibodeau JT, Reay RE, Rasmusson K, Rogers JG, Starling RC (2020) Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America. J Card Fail 26(6):448–456. https://doi.org/10.1016/j.cardfail.2020.04.008
Abnousi F, Kang G, Giacomini J, Yeung A, Zarafshar S, Vesom N, Ashley E, Harrington R, Yong C (2019) A novel noninvasive method for remote heart failure monitoring: the EuleriAn video Magnification apPLications In heart Failure studY (AMPLIFY). NPJ Digit Med 2(1):1–6
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial [published correction appears in Lancet. 2012 Feb 4;379(9814):412]. Lancet 377(9766):658–666. https://doi.org/10.1016/S0140-6736(11)60101-3
Andersson C, Gerds T, Fosbøl E, Phelps M, Andersen J, Lamberts M, Holt A, Butt JH, Madelaire C, Gislason G, Torp-Pedersen C (2020) Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study. Circ Heart Fail 13(6):e007274. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007274
UMAPATHI P, CUOMO K, RILEY S, HUBBARD A, MENZEL K, SAUER E, GILOTRA NA Transforming ambulatory heart failure care in the coronavirus disease-19 era: initial experience from a heart failure disease management clinic. J Card Fail 26(7):637–638. https://doi.org/10.1016/j.cardfail.2020.06.003
Badreldin HA, Atallah B (2020) Global drug shortages due to COVID-19: impact on patient care and mitigation strategies. Res Soc Adm Pharm S1551-7411(20)30569–6. https://doi.org/10.1016/j.sapharm.2020.05.017
Ambrosi P (2020) Comment on “Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China” by Ren et al. J Heart Lung Transplant 39(7):729. https://doi.org/10.1016/j.healun.2020.04.002
Ren ZL, Hu R, Wang ZW, Zhang M, Ruan YL, Wu ZY, Wu HB, Hu XP, Hu ZP, Ren W, Li LC (2020) Epidemiological and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: a descriptive survey report. J Heart Lung Transplant 39(5):412–417. https://doi.org/10.1016/j.healun.2020.03.008
Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumbreras C (2020) COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 20(7):1849–1858. https://doi.org/10.1111/ajt.15929
Li F, Cai J, Dong N (2020) First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant 39(5):496–497
DeFilippis EM, Farr MA, Givertz MM (2020) Challenges in heart transplantation in the era of COVID-19. Circulation 141(25):2048–2051. https://doi.org/10.1161/CIRCULATIONAHA.120.047096
Latif F, Farr MA, Clerkin KJ, Habal MV, Takeda K, Naka Y, Restaino S, Sayer G, Uriel N (2020) Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. JAMA Cardiol e202159. https://doi.org/10.1001/jamacardio.2020.2159
Guidance for cardiothoracic transplant and ventricular assist device centers regarding the SARS CoV-2 pandemic [Internet]. Ishlt.org. (2020). Available from: https://ishlt.org/ishlt/media/documents/SARS-CoV-2_-Guidance-for-Cardiothoracic-Transplant-and-VAD-centers.pdf. Accessed 27 Apr 2020
Patel KJ, Kao T, Geft D, Czer L, Esmailian F, Kobashigawa JA, Patel JK (2020) Donor organ evaluation in the era of coronavirus disease 2019: a case of nosocomial infection. J Heart Lung Transplant 39(6):611–612. https://doi.org/10.1016/j.healun.2020.04.005
Ankersmit HJ, Tugudea S, Spanier T, Weinberg AD, Artrip JH, Burke EM, Flannery M, Mancini D, Rose EA, Edwards NM, Oz MC (1999) Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist de vice. Lancet 354(9178):550–555
Kimball PM, Flattery M, McDougan F, Kasirajan V (2008 May 1) Cellular immunity impaired among patients on left ventricular assist device for 6 months. Ann Thorac Surg 85(5):1656–1661
Radley G, Pieper IL, Ali S, Bhatti F, Thornton CA (2018) The inflammatory response to ventricular assist devices. Front Immunol 9:2651
Kilic A, Acker MA, Atluri P (2015) Dealing with surgical left ventricular assist device complications. J Thorac Dis 7(12):2158–2164
Singh R, Domenico C, Rao S, Urgo K, Prenner S, Wald J, Atluri P, Birati EY (2020) Novel coronavirus disease 2019 in a patient on durable left ventricular assist device support. J Card Fail 26(5):438–439. https://doi.org/10.1016/j.cardfail.2020.04.007